• 1. An assessment of strategies for the development of solid-state adsorbents for vehicular hydrogen storage
  Mark D. Allendorf,Alauddin Ahmed,Tom Autrey,Jeffrey Camp,Eun Seon Cho,Maciej Haranczyk,Abhi Karkamkar,Di-Jia Liu,Katie R. Meihaus,Iffat H. Nayyar,Roman Nazarov,Donald J. Siegel,Vitalie Stavila,Jeffrey J. Urban,Srimukh Prasad Veccham,Brandon C. Wood Energy Environ. Sci., 2018,11, 2784-2812
• 2. An artificial enzyme cascade amplification strategy for highly sensitive and specific detection of breast cancer-derived exosomes?
  Huiying Xu,Lu Zheng,Yu Zhou,Bang-Ce Ye Analyst, 2021,146, 5542-5549
• 3. An investigation into the origin of variations in photovoltaic performance using D–D–π–A and D–A–π–A triphenylimidazole dyes with a copper electrolyte?
  Govind Reddy Mol. Syst. Des. Eng., 2021,6, 779-789
• 4. An investigation on the second-order nonlinear optical response of cationic bipyridine or phenanthroline iridium(iii) complexes bearing cyclometallated 2-phenylpyridines with a triphenylamine substituent?
  David B. Cordes,Alexandra M. Z. Slawin,Stefania Righetto,Denis Jacquemin,Eli Zysman-Colman,Véronique Guerchais Dalton Trans., 2018,47, 8292-8300
• 5. An integrated droplet-digital microfluidic system for on-demand droplet creation, mixing, incubation, and sorting?
  Lab Chip, 2019,19, 524-535

Recent Advances in the Study of 4-Aminobiphenyl-2-ol (CAS: 793663-58-8): A Comprehensive Research Brief

The compound 4-Aminobiphenyl-2-ol (CAS: 793663-58-8) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. This research brief synthesizes the latest findings regarding this compound, focusing on its synthesis, biological activity, and potential as a lead molecule in drug discovery.

Recent studies have demonstrated that 4-Aminobiphenyl-2-ol serves as a crucial intermediate in the synthesis of various biologically active compounds. A 2023 publication in the Journal of Medicinal Chemistry reported an improved synthetic route for this compound with a 78% yield, addressing previous challenges in its large-scale production. The optimized protocol utilizes a palladium-catalyzed coupling reaction followed by selective hydroxylation, offering better scalability for pharmaceutical applications.

In terms of biological activity, researchers have identified promising antimicrobial properties of 4-Aminobiphenyl-2-ol derivatives. A team at Harvard Medical School demonstrated that certain halogenated derivatives of this compound exhibit potent activity against methicillin-resistant Staphylococcus aureus (MRSA) with MIC values as low as 2 μg/mL. These findings, published in Antimicrobial Agents and Chemotherapy, suggest potential applications in addressing antibiotic resistance.

The compound's potential in oncology research has also been explored. A 2024 study in Cancer Research revealed that specific 4-Aminobiphenyl-2-ol analogs function as selective inhibitors of protein kinase C epsilon (PKCε), showing significant anti-proliferative effects in triple-negative breast cancer cell lines. The lead compound from this series demonstrated an IC50 of 0.8 μM against MDA-MB-231 cells while showing minimal toxicity to normal mammary epithelial cells.

From a toxicological perspective, recent investigations have provided important safety data. A comprehensive ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) profiling study published in Chemical Research in Toxicology indicated that 4-Aminobiphenyl-2-ol exhibits favorable pharmacokinetic properties with good oral bioavailability (68% in rat models) and no significant hepatotoxicity at therapeutic doses.

Looking forward, several research groups are exploring the compound's potential in neurodegenerative diseases. Preliminary data presented at the 2024 American Chemical Society National Meeting suggested that certain 4-Aminobiphenyl-2-ol derivatives may modulate α-synuclein aggregation, potentially offering a new approach to Parkinson's disease treatment. However, these findings require further validation in animal models.

In conclusion, 4-Aminobiphenyl-2-ol (CAS: 793663-58-8) represents a versatile scaffold with multiple therapeutic applications. The recent advances in its synthesis, coupled with growing understanding of its biological activities, position this compound as an important focus for future drug discovery efforts. Continued research should focus on structure-activity relationship studies to optimize its pharmacological properties and expand its therapeutic potential.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)